Literature DB >> 25243038

Testosterone deficiency and replacement: Myths and realities.

Ethan D Grober1.   

Abstract

Testosterone deficiency, or hypogonadism, is common and may have deleterious effects on men, including decreased overall well-being, reduced sexual function and bone loss. Despite data demonstrating strong links between testosterone deficiency and significant comorbid conditions (including type 2 diabetes and metabolic syndrome as well as the health benefits of testosterone-replacement therapy [TRT]), some physicians are still hesitant to initiate these therapies. Their reluctance is based on a number of prevailing myths associating TRT with adverse prostate health and recent concerns highlighting the possibility of increased cardiovascular risk.

Entities:  

Year:  2014        PMID: 25243038      PMCID: PMC4145700          DOI: 10.5489/cuaj.2309

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  32 in total

1.  Circulating steroid hormones and the risk of prostate cancer.

Authors:  Gianluca Severi; Howard A Morris; Robert J MacInnis; Dallas R English; Wayne Tilley; John L Hopper; Peter Boyle; Graham G Giles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-01       Impact factor: 4.254

2.  Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.

Authors:  Bo Dai; YuanYuan Qu; YunYi Kong; DingWei Ye; XuDong Yao; ShiLin Zhang; ChaoFu Wang; HaiLiang Zhang; WeiYi Yang
Journal:  BJU Int       Date:  2012-09-14       Impact factor: 5.588

3.  Validation of a screening questionnaire for androgen deficiency in aging males.

Authors:  J E Morley; E Charlton; P Patrick; F E Kaiser; P Cadeau; D McCready; H M Perry
Journal:  Metabolism       Date:  2000-09       Impact factor: 8.694

4.  Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.

Authors:  Mohit Khera; Rajib K Bhattacharya; Gary Blick; Harvey Kushner; Dat Nguyen; Martin M Miner
Journal:  J Urol       Date:  2011-07-23       Impact factor: 7.450

5.  Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.

Authors:  Alexander W Pastuszak; Amy M Pearlman; Win Shun Lai; Guilherme Godoy; Kumaran Sathyamoorthy; Joceline S Liu; Brian J Miles; Larry I Lipshultz; Mohit Khera
Journal:  J Urol       Date:  2013-02-08       Impact factor: 7.450

Review 6.  Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review.

Authors:  R Shabsigh; E D Crawford; A Nehra; K M Slawin
Journal:  Int J Impot Res       Date:  2008-09-11       Impact factor: 2.896

7.  Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group.

Authors:  G W Chodak; N J Vogelzang; R J Caplan; M Soloway; J A Smith
Journal:  JAMA       Date:  1991-02-06       Impact factor: 56.272

8.  Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.

Authors:  Robert M Coward; Jay Simhan; Culley C Carson
Journal:  BJU Int       Date:  2008-12-23       Impact factor: 5.588

9.  Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study).

Authors:  T Hugh Jones; Stefan Arver; Hermann M Behre; Jacques Buvat; Eric Meuleman; Ignacio Moncada; Antonio Martin Morales; Maurizio Volterrani; Ann Yellowlees; Julian D Howell; Kevin S Channer
Journal:  Diabetes Care       Date:  2011-03-08       Impact factor: 19.112

10.  Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies.

Authors:  Andrew W Roddam; Naomi E Allen; Paul Appleby; Timothy J Key
Journal:  J Natl Cancer Inst       Date:  2008-01-29       Impact factor: 13.506

View more
  2 in total

1.  The Relation of Androgenetic Alopecia Severity with Epicardial Fat Thickness.

Authors:  Emine Colgecen; Huseyin Ede; Mustafa Fatih Erkoc; Yurdanur Akyuz; Ali Riza Erbay
Journal:  Ann Dermatol       Date:  2016-03-31       Impact factor: 1.444

2.  Steroidogenic effects of Taraxacum officinale extract on the levels of steroidogenic enzymes in mouse Leydig cells.

Authors:  Hyun Joo Chung; Yoohun Noh; Min Su Kim; Ara Jang; Chae Eun Lee; Soon Chul Myung
Journal:  Anim Cells Syst (Seoul)       Date:  2018-11-08       Impact factor: 1.815

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.